GeneBioTech Co Stock

GeneBioTech Co EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of GeneBioTech Co (086060.KQ) as of Jul 19, 2026 is 11.27. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 10.96 — a change of 2.83% (higher).

EV/EBIT

11.27

YoY

2.83%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of GeneBioTech Co is 2026 11.27 . EV/EBIT (Enterprise Value to EBIT) of GeneBioTech Co was 2025 10.96 . It decreases by 2.83% higher compared to the previous year.

The GeneBioTech Co EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2017
18.32 base
Jan 1, 2018
5.83 base
Jan 1, 2019
60.14 base
Jan 1, 2020
31.21 base
Jan 1, 2021
-216.77 base
Jan 1, 2022
20.57 base
Jan 1, 2023
9.50 base
Jan 1, 2024
7.37 base
YEARPRICE-TO-EBIT
2024 7.37
2023 9.50
2022 20.57
2021 -216.77
2020 31.21
2019 60.14
2018 5.83
2017 18.32
2016 14.79
2015 36.21
2014 20.39
2013 107.76
2012 17.08
2011 10.24
2010 9.50
2009 47.28
2008 30.70
2007 9.17
2006 9.59
2005 -
Access this data via the Eulerpool API
Get Free API Key

GeneBioTech Co Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides GeneBioTech Co's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates GeneBioTech Co's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots GeneBioTech Co's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if GeneBioTech Co grows earnings faster than its peers.

GeneBioTech Co Stock analysis

What does GeneBioTech Co do? GeneBioTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneBioTech Co stock

EV/EBIT (Enterprise Value to EBIT) of GeneBioTech Co is 11.27 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — GeneBioTech Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — GeneBioTech Co